Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDA [idarubicin] VS MTZ [mitoxantrone] IN INDUCTION AND INTENSIFICATION TREATMENT OF AML [acute myeloid leukaemia] OR MDS [myelodysplastic syndrome] IN CHILDREN, A PHASE III RANDOMIZED STUDY.

Next Previous
X
Search
Trial Profile

IDA [idarubicin] VS MTZ [mitoxantrone] IN INDUCTION AND INTENSIFICATION TREATMENT OF AML [acute myeloid leukaemia] OR MDS [myelodysplastic syndrome] IN CHILDREN, A PHASE III RANDOMIZED STUDY.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Idarubicin; Mitoxantrone; Tioguanine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 22 Jun 2010 Biomarkers information updated
    • 21 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top